Article

Endothelin receptor antagonist reduces markers of PCa

Author(s):

Charles Bankhead

Chicago-The selective endothelin receptor antagonist atrasentan significantly attenuates changes in biochemical markers of bone metabolism and disease progression in a group of patients with advanced hormone-refractory prostate cancer that had progressed on placebo, according to the results of a randomized clinical trial.

Related Videos
Raymond Xu, MD, answers a question during a Zoom video interview
Raymond Xu, MD, discusses Cost Plus Drugs and urogynecologic medications
Ekene Enemchukwu, MD, on vaginal estrogen for genitourinary syndrome of menopause
Ekene Enemchukwu, MD, on vaginal estrogen for genitourinary syndrome of menopause
Doctor consulting patient | Image Credit: © Liudmila Dutko - stock.adobe.com
Why a personalized approach is key to prolapse and OAB management
Anna Myers, CNP, answers a question during a Zoom video interview
Anna Myers, CNP, on the overlap between urological and gynecological conditions
Sarah Ponce discusses pelvic and vulvovaginal pain among medical trainees
Sarah Ponce discusses pelvic and vulvovaginal pain among medical trainees
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Expert offers advice on starting a sexual wellness/aesthetics practice
Patient talking with doctor | Image Credit: © bongkarn - stock.adobe.com
Expert discusses pelvic pain and vesicovaginal fistula
Shaya Taghechian, MD, answers a question during a video interview
Dr. Taghechian on her women’s sexual health practice
doctor showing a patient some information on a digital tablet | Image Credit: © bongkarn - stock.adobe.com
Expert urges patient education on vaginal estrogen products
Raveen Syan, MD, FPMRS, answers a question during a Zoom video interview
Dr. Syan shares her thoughts on SUFU 2024
Related Content
Hospital waiting room with reception counter at medical facility | Image Credit: © visoot - stock.adobe.com
April 5th 2025

Vaginal prolapse repair and sling surgery significantly reduce UUI

Christina M. Mezes, DO Catherine A. Matthews, MD
"The biggest message from this study is that 60% can expect resolution of UUI, simply by fixing the prolapse and placing a sling, which is not normally indicated for UUI," according to Christina M. Mezes, DO, and Catherine A. Matthews, MD.
Speaking of Urology: Dr. Winter on the use of vaginal estrogen
July 24th 2024

Speaking of Urology: Dr. Winter on the use of vaginal estrogen

Urology Times staff
In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.
FDA grants marketing authorization to at-home diagnostic test for STIs
March 28th 2025

FDA grants marketing authorization to at-home diagnostic test for STIs

Hannah Clarke
The test can deliver diagnostic results for chlamydia, gonorrhea, and trichomoniasis.
Dr. Malik evaluates quality of Reddit content on recurrent UTIs
March 17th 2022

Dr. Malik evaluates quality of Reddit content on recurrent UTIs

Urology Times staff
“I think we as urologists have to be proactive in providing information to our patients so that they avoid financial harm and potentially bodily harm from this sort of misinformation,” says Rena D. Malik, MD.
FDA approves gepotidacin for uncomplicated UTI
March 25th 2025

FDA approves gepotidacin for uncomplicated UTI

Hannah Clarke
The approval is supported by data from the phase 3 EAGLE-2 and EAGLE-3 trials.
Study progresses of sunobinop for interstitial cystitis/bladder pain syndrome
March 11th 2025

Study progresses of sunobinop for interstitial cystitis/bladder pain syndrome

Hannah Clarke
"The findings from this study will help us understand sunobinop’s potential as a possible new treatment option for this chronic disorder,” said Craig Landau, MD.
© 2025 MJH Life Sciences

All rights reserved.